Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
[en] Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis (haplo-PTCY) and unrelated double-unit umbilical cord blood transplantation (dUCBT) are feasible options for treating patients with high-risk acute myelogenous leukemia (AML). This study compared outcomes after dUCBT and haplo-HCT using peripheral blood stem cells (PBSCs) in adult patients with AML in complete remission (CR) who underwent transplantation in European Society for Blood and Marrow Transplantation (EBMT)-affiliated centers. In a population of adults with de novo AML in first or second CR, we compared outcomes after dUCBT (n = 165) and after haplo-PTCY PBSC (n = 544) performed between January 2013 and December 2018. Patients receiving in vivo antithymocyte globulin, Campath, or ex vivo T cell depletion were excluded. The median follow-up was 33 months for the haplo-PTCY arm and 52 months for the dUCBT arm. No statistically significant differences were observed between the 2 arms in the rates of grade II-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 1.31; P = .18), grade III-IV acute GVHD (HR, 1.17; P = .56), chronic GVHD (HR, .86; P = .48), relapse (HR, 1.07; P = .77), nonrelapse mortality (NRM) (HR, .94; P = .77), leukemia-free survival (LFS) (HR, .99; P = .95), or overall survival (OS) (HR, .99; P = .97). Favorable cytogenetic risk was the sole factor predictive of lower relapse incidence (RI). Younger age at transplantation was associated with lower NRM and higher LFS and OS. Both dUCBT and haplo-PTCY with PBSCs can be considered valid approaches for adult AML patients in CR. New strategies should be investigated in both settings to define the most appropriate conditioning regimen and potentially decrease RI and NRM through better immune reconstitution and optimal supportive care.
Disciplines :
Hematology
Author, co-author :
Ruggeri, Annalisa; Hematology and BMT Unit, San Raffaele Scientific Institute, Milano, Italy,
Galimard, Jacques-Emmanuel; Hematology and Cellular Therapy Service, Hôpital Saint Antoine, AP-HP, Paris,
Labopin, Myriam; Hematology and Cellular Therapy Service, Hôpital Saint Antoine, AP-HP, Paris,
Rafii, Hanadi; Eurocord, Hôpital Saint Louis and IUH University Paris VII, Paris, France.
Blaise, Didier; Institut Paoli Calmettes, Marseille, France.
Ciceri, Fabio; Hematology and BMT Unit, San Raffaele Scientific Institute, Milano, Italy.
Diez-Martin, Jose-Luiz; Hematology Department, Hospital GU Gregorio Marañon, Instituto de Investigación
Cornelissen, Jan; Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the
Chevallier, Patrice; Hematology Service, Hôtel Dieu, Nantes, France.
Sanchez-Guijo, Fermin; Hematology Department, University Hospital of Salamanca, USAL-IBSAL, Salamanca,
Nicholson, Emma; Department of Haematology, Royal Marsden Hospital, London, United Kingdom.
Castagna, Luca; Humanitas Cancer Center, Rozzano, Italy.
Forcade, Edouard; CHU Bordeaux, Hôpital Haut-leveque, Bordeaux, France.
Kuball, Jürgen; Department of Hematology,University Medical Centre, Utrecht, the Netherlands.
Rovira, Montserrat; BMT Unit, Department of Hematology, Institute of Hematology & Oncology, Hospital
Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Passweg, JR, Baldomero, H, Bader, P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 52 (2017), 811–817.
Luznik, L, O'Donnell, PV, Symons, HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 14 (2008), 641–650.
Eapen, M, Rocha, V, Sanz, G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 11 (2010), 653–660.
Eapen, M, Klein, JP, Ruggeri, A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 123 (2014), 133–140.
Ruggeri, A, Sanz, G, Bittencourt, H, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 28 (2014), 779–786.
Brunstein, CG, Fuchs, EJ, Carter, SL, et al. Alternative donor transplantation after reduced-intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118 (2011), 282–288.
Fuchs, EJ, O'Donnell, PV, Eapen, M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood 137 (2021), 420–428.
Wagner, JE, Ballen, KK, Zhang, MJ, et al. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Adv 5 (2021), 4064–4072.
Szydlo, R, Goldman, JM, Klein, JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 15 (1997), 1767–1777.
Pourrajab, F, Zare-Khormizi, MR, Hashemi, AS, Hekmatimoghaddam, S., Genetic characterization and risk stratification of acute myeloid leukemia. Cancer Manag Res. 12 (2020), 2231–2253.
Spyridonidis, A, Labopin, M, Savani, BN, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant 55 (2020), 1114–1125.
Przepiorka, D, Weisdorf, D, Martin, P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995), 825–828.
Martin, PJ, Weisdorf, D, Przepiorka, D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 12 (2006), 491–505.
Fine, JP, Gray, RJ., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 94 (1999), 496–509.
Cox, DR., Regression models and life-tables. J R Stat Soc Ser B Methodol. 34 (1972), 187–220.
Ruggeri, A, Labopin, M, Sanz, G, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia 29 (2015), 1891–1900.
Fatobene, G, Volt, F, Moreira, F, et al. Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. Blood Adv 4 (2020), 6327–6335.
Goldsmith, SR, Abid, MB, Auletta, JJ, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood 137 (2021), 3291–3305.
Singh, A, Dandoy, CE, Chen, M, et al. Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome. Transplant Cell Ther., 28, 2022 48.e1-e10.
Sanz, J, Montoro, J, Solano, C, et al. Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 26 (2020), 358–366.
Pascal, L, Tucunduva, L, Ruggeri, A, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Blood 126 (2015), 1027–1032.
Shouval, R, Fein, JA, Labopin, M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol 6 (2019), e573–e584.
Auletta, JJ, Novakovich, JL, Stritesky, GL, et al. Meeting the demand for unrelated donors in the midst of the COVID-19 pandemic: rapid adaptations by the National Marrow Donor Program and its network partners ensured a safe supply of donor products. Transplant Cell Ther. 27 (2021), 133–141.
Garcia, JG, Grillo, S, Cao, Q, et al. Low 5-year health care burden after umbilical cord blood transplantation. Blood Adv 5 (2021), 853–860.
Wachsmuth, LP, Patterson, MT, Eckhaus, MA, Venzon, DJ, Gress, RE, Kanakry, CG, Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 129 (2019), 2357–2373.
Olson, AL, Politikos, I, Brunstein, C, Milano, F, Barker, J, Hill, JA, Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation. Transplant Cell Ther. 27 (2021), 359–362.
Slade, M, Goldsmith, S, Romee, R, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis., 19:e12629, 2017.
